Literature DB >> 8178944

Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.

B Ryffel1, B D Car, H Gunn, D Roman, P Hiestand, M J Mihatsch.   

Abstract

The ability of interleukin-6 (IL-6) to modulate immune parameters and mesangial cell function suggests a role for this cytokine in the development of autoimmune glomerulonephritis. This hypothesis was tested in 6-month-old female (NZB x NZW)F1 mice that were administered recombinant human IL-6 (rhIL-6) (50 and 250 micrograms/kg s.c.) for 12 weeks, resulting in an accelerated and severe form of membranoproliferative glomerulonephritis associated with marked upregulation of mesangial major histocompatibility complex class II antigen and glomerular ICAM-1 expression. To distinguish direct effects of rhIL-6 on the renal mesangium from those mediated through the immune system, (NZB x NZW)F1 mice were immunosuppressed with cyclosporin. Immunosuppression by cyclosporin inhibited the development of glomerulonephritis, decreased class II antigen expression, and abrogated IL-6-mediated effects. Administration of neutralizing anti-IL-6 antibody had no effect on the spontaneous development of glomerulonephritis in (NZB x NZW)F1 mice. This finding, together with undetectable IL-6 serum levels, makes a pathogenetic role of endogenously produced IL-6 in this disease model unlikely. In contrast to (NZB x NZW)F1 mice, parental NZW or BALB/c mice given high doses of rhIL-6 (500 micrograms/kg) or recombinant murine IL-6 (100 micrograms/kg) daily for 4 weeks failed to develop morphological or biochemical evidence of glomerulonephritis. Induction of acute phase proteins, anemia, thrombocytosis, and induction of renal class II antigen confirmed the biological activity of IL-6 in these mice. In conclusion, while non-nephritogenic in normal mice, IL-6 accelerates the development of the genetically determined glomerulonephritis of (NZB x NZW)F1 mice through effects mediated by a modulated immune system. Since neutralizing IL-6 antibody treatment did not prevent the development of glomerulonephritis, it is unlikely that increased IL-6 production plays a role in the pathogenesis of lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8178944      PMCID: PMC1887352     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

Review 1.  The immunology and pathology of NZB mice.

Authors:  J B Howie; B J Helyer
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

2.  Enhancement of the interleukin 2 receptor expression on T cells by multiple B-lymphotropic lymphokines.

Authors:  T Noma; T Mizuta; A Rosén; T Hirano; T Kishimoto; T Honjo
Journal:  Immunol Lett       Date:  1987-07       Impact factor: 3.685

3.  CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.

Authors:  J D Mountz; H R Smith; R L Wilder; J P Reeves; A D Steinberg
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

4.  Soluble aggregates of IgG and immune complexes enhance IL-6 production by renal mesangial cells.

Authors:  M E van den Dobbelsteen; F J van der Woude; W E Schroeijers; L A van Es; M R Daha
Journal:  Kidney Int       Date:  1993-03       Impact factor: 10.612

5.  B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells.

Authors:  R D Garman; K A Jacobs; S C Clark; D H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Glomerulonephritis in NZB/W mice: therapeutic effect of cyclosporine.

Authors:  H C Gunn; B Ryffel
Journal:  Clin Nephrol       Date:  1986       Impact factor: 0.975

7.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.

Authors:  C O Jacob; H O McDevitt
Journal:  Nature       Date:  1988-01-28       Impact factor: 49.962

8.  Purification and NH2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas.

Authors:  J Van Snick; S Cayphas; A Vink; C Uyttenhove; P G Coulie; M R Rubira; R J Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

9.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.

Authors:  C O Jacob; P H van der Meide; H O McDevitt
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  47 in total

Review 1.  Tumour necrosis factor and other cytokines in murine lupus.

Authors:  A N Theofilopoulos; B R Lawson
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

Review 3.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

4.  Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion.

Authors:  Mileka R Gilbert; Diane G Carnathan; Patricia C Cogswell; Li Lin; Albert S Baldwin; Barbara J Vilen
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

5.  IL-6 Trans-Signaling Drives Murine Crescentic GN.

Authors:  Gerald S Braun; Yoshikuni Nagayama; Yuichi Maruta; Felix Heymann; Claudia R van Roeyen; Barbara M Klinkhammer; Peter Boor; Luigi Villa; David J Salant; Ute Raffetseder; Stefan Rose-John; Tammo Ostendorf; Jürgen Floege
Journal:  J Am Soc Nephrol       Date:  2015-06-03       Impact factor: 10.121

6.  Thermodynamic analysis of monoclonal antibody binding to duplex DNA.

Authors:  J Tanha; J S Lee
Journal:  Nucleic Acids Res       Date:  1997-04-01       Impact factor: 16.971

7.  Correction or transfer of immunodeficiency due to TNF-LT alpha deletion by bone marrow transplantation.

Authors:  M Müller; H P Eugster; M Le Hir; A Shakhov; F Di Padova; C Maurer; V F Quesniaux; B Ryffel
Journal:  Mol Med       Date:  1996-03       Impact factor: 6.354

8.  Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN.

Authors:  Carole Henique; Guillaume Bollee; Olivia Lenoir; Neeraj Dhaun; Marine Camus; Anna Chipont; Kathleen Flosseau; Chantal Mandet; Masayuki Yamamoto; Alexandre Karras; Eric Thervet; Patrick Bruneval; Dominique Nochy; Laurent Mesnard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

9.  Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane.

Authors:  M Satoh; A Kumar; Y S Kanwar; W H Reeves
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 10.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.